stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) Free cash flow
Novartis AG's free cash flow for fiscal 2025 was $15.4B, up 10.4% from $14.0B in fiscal 2024. Over the twelve months to 30 September 2026 it was $14.1B. Over the past ten years it has ranged from $9.3B (fiscal 2015) to $15.4B (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. Novartis AG ranks 6th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $15.4B | 10.38% |
| FY2024 | $14.0B | 0.53% |
| FY2023 | $13.9B | 12.75% |
| FY2022 | $12.3B | (5.83%) |
| FY2021 | $13.1B | 13.48% |
| FY2020 | $11.5B | (12.62%) |
| FY2019 | $13.2B | 5.17% |
| FY2018 | $12.5B | 18.31% |
| FY2017 | $10.6B | 10.44% |
| FY2016 | $9.6B | 3.83% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $4.8B | (7.98%) |
| Jun 2026 | $5.2B | 81.54% |
| Mar 2026 | $2.9B | 109.56% |
| Dec 2025 | $1.4B | (76.52%) |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| JNJ Johnson & Johnson compare | $21.0B |
| ABBV AbbVie Inc. compare | $18.9B |
| MRK Merck & Co., Inc. compare | $16.1B |
| NVS Novartis AG | $14.1B |
| GILD Gilead Sciences, Inc. compare | $13.8B |
| PFE Pfizer Inc. compare | $11.8B |
| AMGN Amgen Inc. compare | $9.6B |
| NVO Novo Nordisk A/S compare | $7.6B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on NVS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement